Thyroid Diseases: Flux G

Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M, Anonymous00045. · Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany. · Eur J Nucl Med Mol Imaging. · Pubmed #18491092 No free full text.

Abstract: INTRODUCTION: The purpose of the EANM Dosimetry Committee Series on "Standard Operational Procedures for Pre-therapeutic Dosimetry" (SOP) is to provide advice to scientists and clinicians on how to perform pre-therapeutic and/or therapeutic patient-specific absorbed dose assessments. MATERIAL AND METHODS: This particular SOP gives advice on how to tailor the therapeutic activity to be administered for systemic treatment of differentiated thyroid cancer (DTC) such that the absorbed dose to the blood does not exceed 2 Gy (a widely accepted limit for bone marrow toxicity). The methodology of blood-based dosimetry has been developed in the 1960s and refined in a series of international multi-centre trials in the framework of the introduction of new diagnostic and therapeutic tools, e.g. recombinant human thyroid-stimulating hormone in the management of DTC. CONCLUSION: The intention is to guide the user through a series of measurements and calculations which the authors consider to be the best and most reproducible way at present.

Haq M, Hyer S, Flux G, Cook G, Harmer C. · Thyroid Unit, Royal Marsden Hospital, Surrey, London, UK. · Br J Radiol. · Pubmed #17495053 links to  free full text

Abstract: Thyrotoxicosis due to functioning metastases in differentiated thyroid cancer (DTC) is exceedingly rare. We report a case of follicular carcinoma in a 54-year-old manager, who presented with thyrotoxicosis, shortness of breath and lung metastases. Transbronchial biopsy of a pulmonary nodule demonstrated normal thyroid. This was interpreted as representing very well-differentiated thyroid cancer. CT, (131)I whole-body imaging and dosimetry is described following total thyroidectomy and repeated radioiodine administration (cumulative activity 34.6 GBq). The patient became asymptomatic with almost complete eradication of the pulmonary metastases. Potential complications of thyroid storm, bone marrow failure and pulmonary fibrosis following radioiodine are discussed, together with methods to minimise these risks.

Flux G, Bardies M, Chiesa C, Monsieurs M, Savolainen S, Strand SE, Lassmann M. · No affiliation provided · Eur J Nucl Med Mol Imaging. · Pubmed #17565497 No free full text.

This publication has no abstract.